NCT03913455View on ClinicalTrials.gov

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

April 14, 2021

Study Completion Date

February 2, 2022

Conditions
Small Cell Lung CancerExtensive-stage Small Cell Lung Cancer
Interventions
DRUG

Guadecitabine

Guadecitabine 30 mg/m2 subcutaneously Days 1-5

DRUG

Carboplatin

Carboplatin AUC 4 IV Day 5

Trial Locations (4)

22908

University of Virginia Health System, Charlottesville

46202

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis

47303

IU Health Ball Memorial Cancer Center, Muncie

53226

University of Wisconsin, Clinical Cancer Center, Milwaukee

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Indiana University School of Medicine

OTHER

lead

Shadia Jalal, MD

OTHER